Shares of medical device company ResMed (NYSE:RMD) fell 2.6% in the afternoon session after its Chairman and CEO, Michael J. Farrell, sold shares worth $1.25 million. The transaction involved the sale ...

ResMed has been growing, and investing in further growth as well -- especially via digital technologies. Its stock is appealingly priced at recent levels. It's worth a closer look. First, a little ...

I confess: I've been sleeping on ResMed (NYSE: RMD) stock, not paying much attention to it at all. But maybe I shouldn't ignore it -- and you may not want to, either. Here are three reasons why it's ...

53% of people surveyed rank sleep as the most important behavior for a long, healthy life, ahead of diet and exercise. Over half of respondents get quality sleep on only four nights a week or less.

Breaking space news, the latest updates on rocket launches, skywatching events and more! You are now subscribed Your newsletter sign-up was successful Want to add more newsletters? Delivered daily ...

SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed (RMD.N), opens new tab plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style ...

The ongoing "wet dress rehearsal" is targeting a simulated liftoff at 9 p.m. ET tonight (Feb. 2). When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business model. I rate RMD a strong sell due to the imminent threat from Apnimed's ...

(RTTNews) - Resmed Inc (RMD.AX) released earnings for its second quarter that Increases, from last year The company's earnings totaled $392.59 million, or $2.68 per share. This compares with $344.62 ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal second-quarter net income of $392.6 million. On a per-share basis, the San Diego-based company said it had net income of ...

ResMed beat estimated earnings by 4.0%, reporting an EPS of $2.81 versus an estimate of $2.71. Revenue was up $140.81 million from the same period last year. The company beat on EPS by $0.05 in the ...